OTC · Biotechnology

Eiger BioPharmaceuticals, Inc. (EIGRQ) Stock

$8.50 +6.25% OTC: EIGRQ Healthcare

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases.

Valuation

MetricValue
Price$8.50
Market Cap$12.59M
P/E Ratio-0.17
P/B Ratio-0.87
P/S Ratio0.80
EPS (TTM)$-50.78
52-Week High$16.00
52-Week Low$1.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-367.00%
ROA-192.97%
ROCE497.24%
Gross Margin95.09%
Operating Margin-455.12%
Net Margin-475.26%
Debt/Equity-2.85
Current Ratio0.71

Annual Financials (USD)

Metric20192020202120222023
Revenue$0$0$12.0M$13.0M$16.0M
Operating Profit$-69.0M$-62.0M$-77.0M$-93.0M$-72.0M
Net Profit$-70.0M$-65.0M$-34.0M$-97.0M$-75.0M
EPS$-92.50$-69.34$-29.98$-69.74$-50.78
Op Margin——-633.7%-687.8%-455.1%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$105.0M$144.0M$127.0M$120.0M$39.0M
Total Liabilities$49.0M$49.0M$54.0M$65.0M$53.0M
Cash$39.0M$29.0M$22.0M$26.0M$25.0M
Borrowings$32.0M$33.0M$33.0M$40.0M$41.0M

Latest News

Dow Jones Futures: Google, Tesla Fall On Earnings, Capital Spending Investor's Business Daily · Jul 23, 2026 Australia jobs blow past expectations in June, cements bets of another rate rise Reuters · Jul 23, 2026 Bitwise CIO Names 2 Crypto Bets Best Positioned for the Next Bull Market BeInCrypto · Jul 23, 2026 MegazoneCloud and Korean Re Sign Strategic Agreement to Advance AX PR Newswire · Jul 23, 2026 Messi-less Miami beat Fire 3-2 to spoil Lewandowski's MLS debut AFP · Jul 23, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-64.0M$-63.0M$-72.0M$-83.0M$-75.0M
Investing Cash Flow$-33.0M$-90.0M$13.0M$19.0M$148.0M
Financing Cash Flow$0$1.0M$0$-1.0M$0
Net Cash Flow$-22.0M$-11.0M$-7.0M$4.0M$0
Free Cash Flow$-64.0M$-63.0M$-120.0M$-83.0M$-75.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.41
FCF Yield-594.13%
Quick Ratio0.68
Interest Coverage-13.13
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases. The company's marketed product, Zokinvy, is prescribed for patients suffering from Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its development pipeline includes several key candidates: Lonafarnib: An orally administered farnesylation inhibitor that has successfully concluded Phase 3 clinical trials for HDV infection. Peginterferon Lambda (lambda): Currently in clinical development for HDV, this compound is also being investigated in Phase II and III investigator studies for mild to moderate COVID-19. Avexitide: This therapy is in Phase II trials for treating congenital hyperinsulinism and post-bariatric hypoglycemia. Based in Palo Alto, California, the company recently announced a significant corporate event: on April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliated entities, submitted a voluntary petition for reorganization under Chapter 11 to the U.S. Bankruptcy Court for the Northern District of Texas.

Eiger BioPharmaceuticals, Inc. is headquartered in US.

Eiger BioPharmaceuticals, Inc. (EIGRQ) stock trades at $8.50 with a market capitalization of $12.59M. The stock is valued at a price-to-earnings (P/E) ratio of -0.17, price-to-book of -0.87, price-to-sales of 0.80. Over the past 52 weeks the stock has ranged between $1.10 and $16.00, and currently trades 46.9% below its 52-week high.

On profitability, Eiger BioPharmaceuticals, Inc. generates a return on equity (ROE) of -367.00%, return on capital employed of 497.24%, an operating margin of -455.12%, a net profit margin of -475.26%.

Official website: www.eigerbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides